الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 136 |  |  |
| | | from | 136 | | |
Abstract
Summary
This study was a prospective single center randomized study, conducted on 220 Egyptian patients with chronic HCV not responding to previous treatment with sofosbuvir and daclatasvir with or without ribavirin. All of the 220 participants received treatment for HCV infection in the form of sofosbuvir and the combination of paritaprevir-ritonavir, ombitasvir with ribavirin for duration of 12 weeks . The results of the study showed that :
• The efficacy of sofosbuvir and the combination of paritaprevir-ritonavir, ombitasvir with ribavirin was 95% .
• Regarding the relation between the response and Fib-4 score, there is no significant correlation between them.
• There is significant improvement in laboratory data as regard liver enzymes , and complete blood picture before , during and in the follow up after the end of treatment .
• The majority of the followed up patients; reported no side effects (94.6%). There were no statistically significant differences between both treatment groups regarding side effects of treatment.
• There is no difference in response betwwen cirrhotic and non-cirrhotic patients.